COVID-19 Spike protein (S) Virus-Like Particle was packaged in HEK293T cells using our proprietary technology. It is the replication-incompetent particles in which the native, full-length COVID-19 S protein (with 6His-tag at its C-terminal) was pseudo-typed as the lentiviral particles’ surface envelope protein. [Note: This VLP has the Spike protein already expressed / presented at the surface of lentiviral particles to mimic coronavirus. It is not used as lentivirus for over-expression of the Spike protein. For over-expressing COVID-19 S protein, please use lentivirus product, CAT#: LVP1329.]
This VLP packaged the Firefly Luciferase as the particle’s virion genomic material. When the COVID-19 S protein binding receptor (such as ACE2) is present in the cell surface, this VLP will bind onto the cells. Its luciferase core may or may not be expressed depending upon the properties of COVID-19 S-protein (i.e whether or not the viral Luciferase core can enter the cell’s cytoplasm after the binding). A luciferase assay, using D-luciferin substrate, can be used to detect the luciferase expression.
COVID-19 S Protein VLP has been tested in response to the binding of anti-S antibody in ELISA plate. The S protein was assembled as surface antigens for use in the development of COVID-19 diagnostics and in vaccine development and other validation assays for COVID-19 coronavirus. This VLP can be detected by anti-C-terminal 6His-tag antibody because the S protein was tagged by C-term 6His-tag.
The VLP’s titer was measured via ELISA P24 assay. Every single particle assembled many S protein molecular at its surface. See more details in Product Manual.
Amount: 200ul/vial at 1×108 VP/ml.